

Supplementary Figure S1. Proportion of PD-L1 Expression in Patients with Targetable Genomic Alterations

PD-L1 TPS		TPS < 1%		TPS 1 - 49 %		TPS ≥ 50%	
	all	n	%	n	%	n	%
EGFR (p.L858R; p.E709K)	2	0	0	2	100	0	0
KRAS G12C	25	3	12	3	12	19	76
MET Ex14skip	24	6	25	6	25	12	50
BRAF V600E	2	0	0	1	50	1	50
CCDC6-RET fusion	3	0	0	2	67	1	33
EML4-Alk (E13A20) fusion	2	1	50	0	0	1	50